Carboplatin and Osteosarcoma - a phase IV clinical study of FDA data

Summary:

Osteosarcoma is reported as a side effect among people who take Carboplatin (carboplatin), especially for people who are male, 10-19 old, also take Cyclophosphamide, and have Germ cell cancer.

The phase IV clinical study analyzes which people have Osteosarcoma when taking Carboplatin. It is created by eHealthMe based on reports of 127,949 people who have side effects when taking Carboplatin from the FDA, and is updated regularly.

What is Carboplatin?

Carboplatin has active ingredients of carboplatin. It is often used in cancer. eHealthMe is studying from 128,210 Carboplatin users. Check the latest studies of Carboplatin.

What is Osteosarcoma?

Osteosarcoma (a cancerous (malignant) bone tumour) is found to be associated with 38 drugs and 112 conditions by eHealthMe. Check the latest studies of Osteosarcoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

127,949 people reported to have side effects when taking Carboplatin.
Among them, 36 people (0.03%) have Osteosarcoma.

Among these 36 people:

What is the gender of people who have Osteosarcoma when taking Carboplatin? *

female: 40 %
male: 60 %

What is the age of people who have Osteosarcoma when taking Carboplatin? *

What are other drugs people take besides Carboplatin? *

What are other side effects people have besides Osteosarcoma? *

Second Primary Malignancy (after getting cure a cancer, a new cancer development): 8 people, 22.22%
Nephropathy Toxic (damage to kidney due to toxins): 5 people, 13.89%
Visual Impairment: 4 people, 11.11%
Disease Progression: 3 people, 8.33%
Swelling Face: 3 people, 8.33%
Cardiotoxicity (damage to the heart muscle): 3 people, 8.33%
Metastases To Lung (cancer spreads to lung): 3 people, 8.33%
Hearing Loss: 3 people, 8.33%
Body Height Below Normal: 2 people, 5.56%
Medulloblastoma Recurrent (reoccurrence of a fast-growing, high-grade tumour that always begins in the cerebellum): 2 people, 5.56%

What are the existing conditions these people have? *

Germ Cell Cancer: 5 people, 13.89%
Retinoblastoma (tumour of retina): 3 people, 8.33%
Neuroblastoma (a cancer that forms in your nerve tissue): 3 people, 8.33%
Hodgkin's Lymphoma (cancer originating from white blood cells): 3 people, 8.33%
Osteosarcoma Metastatic (a cancerous (malignant) bone tumour can spreads to other parts): 2 people, 5.56%
Lymphoma (cancer that begins in immune system cells): 2 people, 5.56%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 1 person, 2.78%
Metastases To Lung (cancer spreads to lung): 1 person, 2.78%
Mediastinum Neoplasm (tumour in mediastinum): 1 person, 2.78%
Malignant Mediastinal Neoplasm (cancerous growths that form in the area of the chest that separates the lungs): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Carboplatin and have Osteosarcoma?

- Check whether Osteosarcoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carboplatin:

Carboplatin (128,210 reports)

Osteosarcoma treatments and more:

Osteosarcoma (3,230 reports)

Browse all side effects of Carboplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteosarcoma:

Osteosarcoma (38 drugs)

Browse all the conditions that are associated with Osteosarcoma:

Osteosarcoma (112 conditions)

Related publications that referenced our studies

Zakaria S, Lu KY, Nussenblatt V, Browner I, "Atrial flutter associated with carboplatin administration", Annals of Pharmacotherapy, 2011 Nov .
Zakaria S, Lu KY, Nussenblatt V, Browner I, "Atrial flutter associated with carboplatin administration", Annals of Pharmacotherapy, 2011 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on carboplatin (the active ingredients of Carboplatin) and Carboplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.